Chinese Patent Medicine as Adjuvant for Mild-to-Moderate Active Ulcerative Colitis: A Network Meta-Analysis of Randomized Controlled Trials.
Chinese Patent Medicine as Adjuvant for Mild-to-Moderate Active Ulcerative Colitis: A Network Meta-Analysis of Randomized Controlled Trials.
复制标题
中成药辅助治疗轻中度活动性溃疡性结肠炎：随机对照试验的网络荟萃分析
DOI：
10.1155/2021/1075886
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Liu ZL
中科院分区：
文献类型：
--
作者：
Sun YX;Yang GY;Karamacoska D;Wang X;Li YX;Hou WB;Zheng YY;Liu JP;Liu ZL
采用网络荟萃分析（NMA）评价中成药治疗轻中度活动期溃疡性结肠炎（UC）的有效性和安全性。 我们系统检索了PubMed、科克伦图书馆、Embase、Sino-Med、中国知网（CNKI）、万方、中文科技期刊数据库（VIP）数据库，检索时间截止至2020年10月。我们纳入了关于中成药治疗轻中度活动期UC的随机对照试验（RCT）。网络子分析和标准成对比较补充了主要分析。还评价了统计异质性、不一致性和排序概率。 数据库检索识别出3222篇引文，其中33篇RCT涉及2971例患者，符合纳入标准。共分析了15种中成药。纳入研究的总体质量较低。配对Meta分析显示中成药在改善临床症状消失、复发率和马约评分方面上级美沙拉嗪。基于不良事件的减少，NMA的结果显示锡类散联合美沙拉秦比其他药物更有效。其他NMA结果显示，丹参冻干粉联合美沙拉秦（RR：0.13; 95%CI，0.02-0.78）和康复新洗剂联合美沙拉秦（RR：0.24; 95%CI，0.07-0.57）在降低复发率方面优于美沙拉秦（上级）。另一项NMA结果显示康复新洗剂联合美沙拉秦（RR：0.00; 95%CI，0.00-0.02）和脂康胶囊联合美沙拉秦（RR：0.00; 95%CI，0.00-0.02）在增加里急后重消失方面上级美沙拉秦。 在概率排序中，锡类散联合美沙拉秦不良事件最少，排在首位;保肠止泻丸联合美沙拉秦复发率最低，排在首位;锡类散联合美沙拉秦改善粘液脓性血便/腹痛消失率最高，康复新洗剂联合美沙拉秦治疗腹泻/里急后重的消失率最高。然而，目前尚无治疗UC的中成药之间的直接比较。未来需要更多的多组随机对照试验来提供直接的比较证据。
To evaluate the effectiveness and safety of Chinese patent medicine for mild-to-moderate active ulcerative colitis (UC) using network meta-analysis (NMA). We systematically searched PubMed, Cochrane library, Embase, Sino-Med, China National Knowledge Infrastructure (CNKI), Wanfang, and Chinese Scientific Journal Database (VIP) databases to October, 2020. We included randomized controlled trials (RCTs) on Chinese patent medicine for mild-to-moderate active UC. The main analysis was complemented by network subanalyses and standard pairwise comparisons. Statistical heterogeneity, inconsistencies, and ranking probability were also evaluated. The databases search identified 3222 citations, of which 33 RCTs involving 2971 patients met the inclusion criteria. A total of 15 Chinese patent medicines were analyzed. The overall quality of the included studies was low. Pairwise meta-analysis showed that Chinese patent medicine was superior to Mesalazine in improving disappearances of clinical symptoms, recurrence rate, and Mayo score. Based on decreases in adverse events, results from NMA showed that Xilei powder plus Mesalazine was more effective than other drugs. Other NMA results indicated that Danshen freeze-dried powder plus Mesalazine (RR: 0.13; 95% CI, 0.02–0.78) and Kangfuxin lotion plus Mesalazine (RR: 0.24; 95% CI, 0.07–0.57) were superior to Mesalazine in decreasing recurrence rate. Another NMA result indicated that Kangfuxin lotion plus Mesalazine (RR: 0.00; 95% CI, 0.00–0.02) and Zhi Kang capsule plus Mesalazine (RR: 0.00; 95% CI, 0.00–0.02) were superior to Mesalazine in increasing the disappearance of tenesmus. In the probability sorting, Xilei powder combined with Mesalazine ranked first for having the fewest adverse events, Maintaining Intestines Antidiarrheal Pills combined with Mesalazine ranked first for having the lowest recurrence rate, Xilei powder combined with Mesalazine ranked first for improving disappearance rate of mucopurulent bloody stool/abdominal pain, and Kangfuxin lotion combined with Mesalazine ranked first for improving the disappearance rate of diarrhea/tenesmus. However, there is a lack of direct comparisons among Chinese patent medicines for UC. More multiarm RCTs are needed in the future to provide direct comparative evidence.
登录
查看更多内容
影响因子：
39.2
作者：
Hutton, Brian;Salanti, Georgia;Moher, David
通讯作者：
Moher, David
影响因子：
28.3
作者：
Franzosa, Eric A.;Sirota-Madi, Alexandra;Xavier, Ramnik J.
通讯作者：
Xavier, Ramnik J.
影响因子：
30.8
作者：
de Lange KM;Moutsianas L;Lee JC;Lamb CA;Luo Y;Kennedy NA;Jostins L;Rice DL;Gutierrez-Achury J;Ji SG;Heap G;Nimmo ER;Edwards C;Henderson P;Mowat C;Sanderson J;Satsangi J;Simmons A;Wilson DC;Tremelling M;Hart A;Mathew CG;Newman WG;Parkes M;Lees CW;Uhlig H;Hawkey C;Prescott NJ;Ahmad T;Mansfield JC;Anderson CA;Barrett JC
通讯作者：
Barrett JC
影响因子：
29.4
作者：
Bressler, Brian;Marshall, John K.;Feagan, Brian
通讯作者：
Feagan, Brian